ArticlePloS one2015
Aptamer-Dendrimer Bioconjugates for Targeted Delivery of miR-34a Expressing Plasmid and Antitumor Effects in Non-Small Cell Lung Cancer Cells.
Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Design strategies for programmable oligonucleotide nanotherapeutics.Drug discovery today · 2020Pooled it
- Inhalable nanoparticle-based drug delivery system for non-small cell lung cancer therapy: promises and challenges.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2025Review
- Integration of MicroRNAs with nanomedicine: tumor targeting and therapeutic approaches.Frontiers in cell and developmental biology · 2025Review
- Enhancing Therapeutic Efficacy in Cancer Treatment: Integrating Nanomedicine with Autophagy Inhibition Strategies.ACS omega · 2024Review
- Targeting microRNAs as a promising anti-cancer therapeutic strategy against traffic-related air pollution-mediated lung cancer.Cancer metastasis reviews · 2024Review
- Targeted therapy using nanocomposite delivery systems in cancer treatment: highlighting miR34a regulation for clinical applications.Cancer cell international · 2023Review
- Nanomedicine for autophagy modulation in cancer therapy: a clinical perspective.Cell & bioscience · 2023Review
- A perspective to weaponize microRNAs against lung cancer.Non-coding RNA research · 2023Review
- Recent advances in nanoparticle applications in respiratory disorders: a review.Frontiers in pharmacology · 2023Review
- Regulatory miRNAs in cancer cell recovery from therapy exposure and its implications as a novel therapeutic strategy for preventing disease recurrence.The Enzymes · 2023Article
- Review
- MicroRNAs and Their Big Therapeutic Impacts: Delivery Strategies for Cancer Intervention.Cells · 2022Review
- Aptamer‑based therapy for targeting key mediators of cancer metastasis (Review).International journal of oncology · 2022Review
- Targeting Inflammasome Activation in COVID-19: Delivery of RNA Interference-Based Therapeutic Molecules.Biomedicines · 2021Review
- Bio-Nanocarriers for Lung Cancer Management: Befriending the Barriers.Nano-micro letters · 2021Review
- Therapeutic advances of miRNAs: A preclinical and clinical update.Journal of advanced research · 2021Review
- Aptamer-Functionalized Nanoparticles in Targeted Delivery and Cancer Therapy.International journal of molecular sciences · 2020Review
- Dendrimers as Modulators of Brain Cells.Molecules (Basel, Switzerland) · 2020Review
- Advances in Oligonucleotide Aptamers for NSCLC Targeting.International journal of molecular sciences · 2020Review
- Aptamers in Non-Small Cell Lung Cancer Treatment.Molecules (Basel, Switzerland) · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metastasis and drug resistance are major barriers for the treatment of non-small cell lung cancer (NSCLC). To explore new therapeutic options, we successfully encapsulated MicroRNA-34a (miR-34a), a potent endogenous tumor suppressor in NSCLC into S6 aptamer-conjugated dendrimer to form lung cancer-targeted gene delivery nanoparticles (PAM-Ap/pMiR-34a NPs). PAM-Ap/pMiR-34a NPs had a diameter of 100-200 nm and Zeta potential of ~30 mV at applied N/P ratio. The aptamer conjugation significantly improved cellular uptake as well as gene transfection efficiency of PAM-Ap/pMiR-34a NPs in cultured NSCLC cells. We showed that PAM-Ap/pMiR-34a NPs enhanced the regulation of targeted genes, BCL-2 and p53 in vitro. In addition, we revealed PAM-Ap/pMiR-34a NPs significantly inhibited cell growth, migration, invasion and induced apoptosis of lung cancer cells compared with non-targeted NPs. The method provided a novel therapeutic strategy for the experimental treatment of NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.